Loading, please wait...
Welcome to the 30th Anniversary Celebration daylong Continuing Education Event!
We are excited that you have decided to spend your day with us. The day will begin with three amazing keynote presentations from alumni of our School of Pharmacy. They will speak on a variety of topics and I am confident you will find their words inspirational. After lunch and networking we will have five different tracks for you to choose from (or you can jump between tracks).
The tracks include community/ambulatory care, hospital/acute care, education, research, and staff development. Most presentations will be 15 minutes in length to allow for small learning burst and allow you to hear from multiple speakers on multiple topics throuhgout the afternoon.
Below you will find all of the programs that will be offered throughout the day and to claim credit, you will simply select the programs you attended, enter the CE code you received at the end of the presentation, and the complete the required evaluation. All credit will automatically be sent to your CPE Monitor.
Thanks again for your interest in this programming!
Date: May 15, 2026 02:15 PM - 03:15 PM
Fee
$0.00
CE Hours
3.50
CE Units
0.350
Registration closes on Jul 14, 2026 11:55 PM
Target Audience(s)
- Pharmacists
Accreditation(s)
|
Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
|
Requirements for CE Credit
In order to receive CE credit, attend LIVE CE and complete the online evaluation.
Fri, May 15, 2026
Fri, May 15, 2026
Objectives
- Define clinical relevance.
- Record clinically relevant interventions in community practice.
- Discuss the importance of intentionality and relationships.
Speaker(s)/Author(s)
|
Joshua Hawver, Pharm.D., RPh Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-039-L99-P
Date:
05/15/26
Time:
02:15 PM - 02:35 PM
CE Hours
0.25
Objectives
- Describe how preceptor behaviors influence licensure readiness and professional development.
- Discuss evidence-informed strategies that promote student accountability and clinical reasoning.
- Identify low-burden learning techniques that align experiential education with NAPLEX success.
Speaker(s)/Author(s)
|
Levi Campbell, Pharm.D. Disclosure : The presenter has no actual or potential conflict of interest related to this presentation. The speaker has no financial relationships with regard to this presentation to disclose. |
Activity Number
0096-0000-26-044-L99-P
Date:
05/15/26
Time:
02:15 PM - 02:35 PM
CE Hours
0.25
Objectives
- Describe two characteristics of effective feedback.
- Discuss the structured feedback approach.
- Identify one strategy for feedback improvement for future use.
Speaker(s)/Author(s)
|
Adam McKee, M.Ed., SPHR Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-053-L99-P
Date:
05/15/26
Time:
02:15 PM - 02:35 PM
CE Hours
0.25
Objectives
- Describe normal aging, mild cognitive impairment, and dementia as they relate to medication management in older adults.
- Identify clinical cues suggesting cognitive decline that may impair medication management in ambulatory care patients.
- Discuss geriatric assessment principles to identify medication-related risks and optimize therapy in ambulatory care.
Speaker(s)/Author(s)
|
Erica P. Dominguez, Pharm.D., BCACP Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-040-L05-P
Date:
05/15/26
Time:
02:35 PM - 02:55 PM
CE Hours
0.25
Objectives
- Describe telepharmacy services in the acute care setting.
- Identify cost savings and other benefits of telepharmacy in the acute care setting.
- Explain potential telepharmacy practice models for the acute care setting.
Speaker(s)/Author(s)
|
Taryn Bainum, Pharm.D., BCPS, BCCCP Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-042-L99-P
Date:
05/15/26
Time:
02:35 PM - 02:55 PM
CE Hours
0.25
Objectives
- Describe common applications of AI for experiential education for pharmacy preceptors and learners.
- Recognize key limitations, challenges, and risks associated with AI use in clinical teaching and practice.
- Discuss best practices for the responsible and effects use of AI in pharmacy experiential settings.
Speaker(s)/Author(s)
|
Amany Iskander, Pharm.D. Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-045-L99-P
Date:
05/15/26
Time:
02:35 PM - 02:55 PM
CE Hours
0.25
Objectives
- Identify what strong collaboration actually looks like.
- Recognize what tends to happen when collaboration breaks down.
- Discuss practical ways we can strengthen partnership in everyday interactions.
Speaker(s)/Author(s)
|
Tanya Fraley Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-052-L99-P
Date:
05/15/26
Time:
02:35 PM - 02:55 PM
CE Hours
0.25
Objectives
- Describe current ACIP recommendations for recombinant herpes zoster vaccine and adult pneumococcal vaccination.
- Explain new product offerings and practical handling differences, including updates for both herpes zoster vaccination and pneumococcal vaccines.
- Discuss current guidelines and product-specific considerations to select and administer appropriate vaccines in adult patients.
Speaker(s)/Author(s)
|
Tyler Skeeler, Pharm.D. Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-041-L06-P
Date:
05/15/26
Time:
02:55 PM - 03:15 PM
CE Hours
0.25
Objectives
- Describe the concept of dose banding and its role in medication standardization and potential operational and financial benefits.
- Discuss the current literature supporting dose banding for selected medications used in hospital practice.
- List key steps required to implement a dose banding program, including policy development, informatics build, and staff education.
Speaker(s)/Author(s)
|
Erica Wilson, Pharm.D. Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-043-L05-P
Date:
05/15/26
Time:
02:55 PM - 03:15 PM
CE Hours
0.25
Speaker(s)/Author(s)
|
Ashley Higbea, Pharm.D., BCPS, FNAP Disclosure : The presenter has no actual or potential conflict of interest related to this presentation. The speaker has no financial relationships with regard to this presentation to disclose. |
Activity Number
0096-0000-26-046-L99-P
Date:
05/15/26
Time:
02:55 PM - 03:15 PM
CE Hours
0.25
Objectives
- Describe the defining characteristics of quality improvement activities.
- Distinguish research from quality improvement using federal regulatory definitions.
- Apply a structured decision-making framework to determine when IRB submission is required.
Speaker(s)/Author(s)
|
Kaytlin Krutsch, PhD, Pharm.D., MBA, BCPS Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-26-051-L99-P
Date:
05/15/26
Time:
02:15 PM - 02:45 PM
CE Hours
0.50
Objectives
- Describe the clinical implications of currently approved 1L and 2L options for metastatic pancreatic cancer.
- Explain the biological importance KRAS as a molecular target and the potential mechanisms to target KRAS.
- Discuss the treatment implications of novel therapeutics on the horizon for patients with metastatic pancreatic cancer.
Speaker(s)/Author(s)
|
Alexander D. Le, Pharm.D. Disclosure : Employee of Ipsen Pharmaceuticals Own stock in TempusAI Neither Ipsen or TempusAI assisted in the development of this content. |
Activity Number
0096-0000-26-048-L01-P
Date:
05/15/26
Time:
02:45 PM - 03:15 PM
CE Hours
0.50